Elicio Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-8.6%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.08next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Disease-Free Survival (DFS) Hazard Ratio in R0 Resected Patients Quarterly65.0%Target: Statistically significant DFS improvement (p < 5) in Phase 3 registrational trial%
mKRAS-Specific T Cell Response Rate Quarterly99.0%Target: Maintain >95% robust T cell response rate in future clinical cohorts
Cash Runway (Quarters of Operations) Quarterly150.0%Target: Extend runway beyond 2026 through strategic partnerships or financing
Watch Items
- Phase 3 Registrational Trial Design and FDA AlignmentTrigger: End-of-Phase 2 meeting with the FDA to finalize protocolAction: Review FDA feedback on the refined Phase 3 strategy focusing on R0 resected patients and extended dosing.
- Strategic Financing and Partnering OpportunitiesTrigger: Cash runway depletion approaching Q4 2026Action: Secure non-dilutive co-development partnerships or execute capital raises under the $400M shelf registration.
- Combination Therapy Clinical Data (ELI-002 7P + Checkpoint Inhibitors)Trigger: Follow-up data on metastatic mKRAS pancreatic cancer patients achieving complete responsesAction: Evaluate clinical trial protocols for combination regimens to expand the addressable market.
Research as of 19 Jun 2026